Skip to main content
SpringerLink
Log in

Complement defects in children which result in kidney diseases: diagnosis and therapy

  • Chapter
Book cover Complement and Kidney Disease

Part of the book series: Progress in Inflammation Research ((PIR))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Warwicker P, Goodship THJ, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P, Goodship JA (1998) Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53: 836–844

    Article  CAS  PubMed  Google Scholar 

  2. Ohali M, Shalev H, Schlesinger M, Katz Y, Kachko L, Carmi R, Sofer S, Landau D (1998) Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr Nephrol 12: 619–624

    Article  CAS  PubMed  Google Scholar 

  3. Pichette V, Quérin S, Schürch W, Brun G, Lehner-Netsch G, Deläge JM (1994) Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 24: 936–941

    CAS  PubMed  Google Scholar 

  4. Roodhooft AM, McLean RH, Elst E, Van Acker KJ (1990) Recurrent haemolytic uraemic syndrome and acquired hypomorphic variant of the third component of complement. Pediatr Nephrol 4: 597–599

    Article  CAS  PubMed  Google Scholar 

  5. Thompson RA, Winterborn MH (1981) Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 46:110–119

    CAS  PubMed  Google Scholar 

  6. Goodship TH, Liszewski MK, Kemp EJ, Richards A, Atkinson JP (2004) Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends Mol Med 10: 226–231

    Article  CAS  PubMed  Google Scholar 

  7. Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, Gamba S, Remuzzi G (2003) Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362: 1542–1547

    Article  CAS  PubMed  Google Scholar 

  8. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumanoglu MH, Kavukcu S, Filler G, Pirson Y et al (2003) Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 100: 12966–12971

    CAS  PubMed  Google Scholar 

  9. Ault BH (2000) Factor H and the pathogenesis of renal disease. Pediatr Nephrol 14: 1045–1053

    Article  CAS  PubMed  Google Scholar 

  10. Brai M, Misiano G, Maringhini S, Cutaja I, Hauptmann G (1988) Combined homozygous factor H and heterozygous C2 deficiency in an Italian family. J Clin Immunol 8: 50–56

    Article  CAS  PubMed  Google Scholar 

  11. Fijen C, Kuijper E, Holdrinet A, Daha M, Dankert J (1992) Factor H deficiency in a Dutch family. Immunobiology 184: 427

    Google Scholar 

  12. Lopez-Larrea C, Dieguez M, Enguix A, Dominguez O, Marin B, Gomez F (1987) A familial deficiency of complement factor H. Biochem Soc Trans 15: 648–649

    Google Scholar 

  13. Nielsen HE, Christensen KC, Koch C, Thomas BS, Heegard NH, Tranum-Jensen J (1989) Hereditary, complete deficiency of complement factor H associated with recurrent meningococcal disease. Scand J Immunol 30: 711–718

    CAS  PubMed  Google Scholar 

  14. Rougier N, Kazatchkine MD, Rougier JP, Fremeaux-Bacchi V, Blouin J, Deschenes G, Soto B, Baudouin V, Pautard B, Proesmans W et al (1998) Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 9: 2318–2326

    CAS  PubMed  Google Scholar 

  15. Friese MA, Hellwage J, Jokiranta TS, Meri S, Müller-Quernheim HJ, Peter HH, Eibel H, Zipfel PF (2000) Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA). Clin Exp Immunol 121: 406–415

    Article  CAS  PubMed  Google Scholar 

  16. Friese MA, Manuelian T, Junnikkala S, Hellwage J, Meri S, Peter HH, Gordon DL, Eibel H, Zipfel PF (2003) Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis. Clin Exp Immunol 132: 485–495

    Article  CAS  PubMed  Google Scholar 

  17. Junnikkala S, Hakulinen J, Jarva H, Manuelian T, Bjorge L, Butzow R, Zipfel PF, Meri S (2002) Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumor cells. Br J Cancer 87: 1119–1127

    Article  CAS  PubMed  Google Scholar 

  18. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S (2000) Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 164: 6075–6081

    CAS  PubMed  Google Scholar 

  19. Devine DV, Siegel RS, Rosse WF (1987) Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platalet survival in vivo. J Clin Invest 79: 131–137

    CAS  PubMed  Google Scholar 

  20. DiScipio RG, Daffern PJ, Schraufstatter IU, Sriramarao P (1998) Human polymor-phonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). J Immunol 160: 4057–4066

    CAS  PubMed  Google Scholar 

  21. Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HPG, Remuzzi G, Zipfel PF (2003) Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 111: 1181–1190

    Article  CAS  PubMed  Google Scholar 

  22. Berner R, Krause MF, Gordjani N, Zipfel PF, Boehm N, Krueger M, Brandis M, Zimmerhackl LB (2002) Hemolytic uremic syndrome due to an altered factor H triggered by neonatal pertussis. Pediatr Nephrol 17: 190–192

    Article  PubMed  Google Scholar 

  23. Filler G, Radhakrishnan S, Strain L, Hill A, Knoll G, Goodship TH (2004) Challenges in management of infantile factor H associated haemolytic uremic syndrome. Pediatr Nephrol 19: 908–911

    PubMed  Google Scholar 

  24. Gerber A, Kirchhoff-Moradpour AH, Obieglo S, Brandis M, Kirschfink M, Zipfel PF, Goodship JA, Zimmerhackl LB (2003) Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality. Pediatr Nephrol 18: 952–955

    Article  PubMed  Google Scholar 

  25. Olie KH, Florquin S, Groothoff JW, Verlaak R, Strain L, Goodship THJ, Weening J, Davin JC (2004) Atypical relapse of hemolytic uremic syndrome after transplantation. Pediatr Nephrol 19: 1173–1176

    Article  PubMed  Google Scholar 

  26. Licht C, Heinen S, Józsi M, Löschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, Kirschfink M, Hoppe B, Zipfel PF (2005) Deletion of a single amino acid (K224) in the regulatory domain of factor H reveals a novel pathomechanism for membranoproliferative glomerulonephritis type II. Submitted

    Google Scholar 

  27. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V (2005) Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16: 555–563

    Article  CAS  PubMed  Google Scholar 

  28. Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, Richards A, Ward R, Goddship JA, Goddship TH (2005) Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 16: 2150–2155

    Article  CAS  PubMed  Google Scholar 

  29. Abbas AK, Lichtman AH, Pober JS (2000) Effector mechanisms of humoral immunity. In: Cellular and Molecular Immunology, 4th edition. WB Saunders Company, Philadelphia, 309–339

    Google Scholar 

  30. Walport MJ (2001) Complement (first of two parts). N Engl J Med 344: 1058–1066

    CAS  PubMed  Google Scholar 

  31. Walport MJ (2001) Complement (second of two parts). N Engl J Med 344: 1140–1144

    CAS  PubMed  Google Scholar 

  32. Young NS (2005) Paroxysmal nocturnal hemoglobinuria: current issues in pathophysiology and treatment. Curr Hematol Rep 4: 103–109

    CAS  PubMed  Google Scholar 

  33. Zipfel PF (2001) Complement factor H: physiology and pathophysiology. Semin Thromb Hemost 27: 191–199

    Article  CAS  PubMed  Google Scholar 

  34. Zipfel PF (2001) Hemolytic uremic syndrome: how do factor H mutants mediate endothelial damage? Trends Immunol 22: 345–348

    Article  CAS  PubMed  Google Scholar 

  35. Zipfel PF, Jokiranta TS, Hellwage J, Koistinen V, Meri S (1999) The factor H protein family. Immunopharmacology 42: 53–60

    Article  CAS  PubMed  Google Scholar 

  36. Zipfel PF, Skerka C (1999) FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function. Immunol Today 20: 135–140

    Article  CAS  PubMed  Google Scholar 

  37. Jószi M, Manuelian T, Heinen S, Oppermann M, Zipfel PF (2004) Attachment of the soluble complement regulator factor H to the cell and tissue surfaces: relevance for pathology. Histol Histopathol 19: 251–258

    Google Scholar 

  38. Quigg RJ (2003) Complement and the kidney. J Immunol 171: 3319–3324

    CAS  PubMed  Google Scholar 

  39. Sánchez-Corral P, Pérez-Caballero D, Huarte O, Simckes AM, Goicoechea E, López-Trascasa M, Rodríguez de Córdoba S (2002) Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 71: 1285–1295

    Article  PubMed  Google Scholar 

  40. Daha MR, Fearon DT, Austen KF (1976) C3nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 116: 1–7

    CAS  PubMed  Google Scholar 

  41. Mathieson PW, Würzner R, Oliviera DBG, Lachmann PJ, Peters DK (1993) Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 177: 1827–1831

    CAS  PubMed  Google Scholar 

  42. Ruggenenti P, Noris M, Remuzzi G (2001) Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60: 831–846

    CAS  PubMed  Google Scholar 

  43. Symmers WS (1952) Thrombotic microangiopathic haemolytic anemia (thrombotic microangiopathy). Br Med J 2: 897–903

    CAS  PubMed  Google Scholar 

  44. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R (1955) Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 85: 905–909

    CAS  PubMed  Google Scholar 

  45. Moschcowitz E (1924) Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 24: 21–24

    Google Scholar 

  46. Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347: 589–600

    Article  CAS  PubMed  Google Scholar 

  47. Donne RL, Abbs I, Barany P, Elinder CG, Little M, Conlon P, Goodship THJ (2002) Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 40: E22

    Article  PubMed  Google Scholar 

  48. Loirat C, Niaudet P (2003) The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 18: 1095–1101

    Article  PubMed  Google Scholar 

  49. Neuman HPH, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Königsrainer A et al (2003) Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 40: 676–681

    Google Scholar 

  50. Taylor CM, Chua C, Howie AJ, Ridson RA (2004) Clinico-pathological findings in diarrhea negative haemolytic uraemic syndrome. Pediatr Nephrol 19: 419–425

    CAS  PubMed  Google Scholar 

  51. Hughes AK, Ergonul Z, Stricklett PK, Kohan DE (2002) Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: upregulation of globotriaosylceramide expression. J Am Soc Nephrol 13:2239–2245

    Article  CAS  PubMed  Google Scholar 

  52. Hughes AK, Stricklett PK, Schmid D, Kohan DE (2000) Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells. Kidney Int 57:2350–2359

    Article  CAS  PubMed  Google Scholar 

  53. Tsai HM (2003) Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 14: 1072–1081

    Article  PubMed  Google Scholar 

  54. Mathieson P (2002) Complement factor H and haemolytic uraemic syndrome. Lancet 359: 801–802

    Article  PubMed  Google Scholar 

  55. Richards A, Goodship JA, Goodship TA (2002) The genetics and pathogenesis of haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Curr Opin Nephrol Hypertens 11: 431–435

    Article  PubMed  Google Scholar 

  56. Taylor CM (2001) Complement factor H and the haemolytic uraemic syndrome. Lancet 358: 1200–1202

    CAS  PubMed  Google Scholar 

  57. Taylor CM (2001) Hemolytic-uremic syndrome and complement factor H deficiency: clinical aspects. Semin Thromb Hemost 27: 185–190

    Article  CAS  PubMed  Google Scholar 

  58. Zipfel PF, Hellwage J, Friese MA, Hegasy G, Jokiranta ST, Meri S (1999) Factor H and disease: a complement regulator affects vital body function. Mol Immunol 36: 241–248

    Article  CAS  PubMed  Google Scholar 

  59. Zipfel PF, Skerka C, Caprioli J, Manuelian T, Neumann HH, Noris M, Remuzzi G (2001) Complement factor H and hemolytic uremic syndrome. Int Immunopharmacol 1: 461–468

    Article  CAS  PubMed  Google Scholar 

  60. Kaplan BS, Chesney RW, Drummond KN (1975) Hemolytic uremic syndrome in families. N Engl J Med 292: 1090–1093

    CAS  PubMed  Google Scholar 

  61. Kaplan BS, Meyers KE, Schulman SL (1998) The pathogenesis of haemolytic uremic syndrome. J Am Soc Nephrol 9: 1126–1133

    CAS  PubMed  Google Scholar 

  62. Noris M, Ruggenenti P, Perna A, Orisio S, Caprioli J, Skerka C, Vasile B, Zipfel PF, Remuzzi G (1999) Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. J Am Soc Nephrol 10: 281–293

    CAS  PubMed  Google Scholar 

  63. Ying L, Katz Y, Schlesinger M, Carmi R, Shalev H, Haider N, Beck G, Sheffield VC, Landau D (1999) Complement factor H gene mutation associated with autosomal recessive atypical haemolytic uremic syndrome. Am J Hum Genet 65: 1538–1546

    Article  CAS  PubMed  Google Scholar 

  64. Buddles MRH, Donne RL, Richards A, Goodship J, Goodship THJ (2000) Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 66: 1721–1722

    Article  CAS  PubMed  Google Scholar 

  65. Caprioli J, Bettinaglio P, Zipfel PF, Amadei B, Daina E, Gamba S, Skerka C, Marziliano N, Remuzzi G, Noris M (2001) The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 12: 297–307

    CAS  PubMed  Google Scholar 

  66. Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Fridman WH, Weiss L (2004) Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 15: 787–795

    Article  CAS  PubMed  Google Scholar 

  67. Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L (2001) Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 138: 412–417

    CAS  PubMed  Google Scholar 

  68. Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, Waldherr R, Kirschfink M, Zipfel PF, Hoppe B (2005) Successful plasma therapy for atypical hemolytic uremic syndrome (aHUS) caused by factor H deficiency due to a mutation in the complement cofactor protein (CCP) domain 15. Am J Kidney Dis 45: 415–421

    Article  CAS  PubMed  Google Scholar 

  69. Pérez-Caballero D, González-Rubio C, Gallardo ME, Vera M, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P (2001) Clustering of missense mutations in the C-terminal region of factor H in atypical haemolytic uremic syndrome. Am J Hum Genet 68: 478–484

    Article  PubMed  Google Scholar 

  70. Richards A, Buddles MR, Donne RL, Kaplan BS, Kirk E, Venning MC, Tielemans CL, Goodship JA, Goodship THJ (2001) Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 68:485–490

    CAS  PubMed  Google Scholar 

  71. Warwicker P, Donne RL, Goodship JA, Goodship THJ, Howie AJ, Kumararatne DS, Thompson RA, Taylor CM (1999) Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrol Dial Transplant 14: 1229–1233

    CAS  PubMed  Google Scholar 

  72. Wyatt RJ, Julian BA, Weinstein A, Rothfield NF, McLean RH (1982) Partial H (beta 1H) deficiency and glomerulonephritis in two families. J Clin Immunol 2: 110–117

    Article  CAS  PubMed  Google Scholar 

  73. Zipfel PF, Neumann HPH, Jozsi M (2003) Genetic screening in haemolytic uraemic syndrome. Curr Opin Nephrol Hypertens 12: 653–657

    PubMed  Google Scholar 

  74. Zipfel PF, Skerka C, Hellwage J, Jokiranta ST, Meri S, Brade V, Kraiczy P, Noris M, Remuzzi G (2002) Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans 30: 971–978

    CAS  PubMed  Google Scholar 

  75. Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M (2003) Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Human Molecular Genetics 12: 3385–3395

    Article  CAS  PubMed  Google Scholar 

  76. Pangburn MK (2002) Localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J Immunol 169: 4702–2706

    CAS  PubMed  Google Scholar 

  77. Hellwage J, Jokiranta TS, Friese MA, Wolk TU, Kampen E, Zipfel PF, Meri S (2002) Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J Immunol 169: 6935–6944

    CAS  PubMed  Google Scholar 

  78. Sánchez-Corral P, González-Rubio C, Rodríguez de Córdoba S, López-Trascasa M (2004) Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 41: 81–84

    PubMed  Google Scholar 

  79. Perkins SJ, Goodship THJ (2002) Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding site. J Mol Biol 316: 217–224

    Article  CAS  PubMed  Google Scholar 

  80. Furlan M, Laemmle B (2000) Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura — new insights into underlying biochemical mechanisms. Nephrol Dial Transplant 15: 1112–1114

    CAS  PubMed  Google Scholar 

  81. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U et al (1998) Von Willebrand factor-cleaving protease in thrombotic-thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339: 1578–1584

    Article  CAS  PubMed  Google Scholar 

  82. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B (1997) Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89: 3097–3103

    CAS  PubMed  Google Scholar 

  83. Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E, Hassenpflug W, Häberle J, Kentouche K, Kohne E et al (2003) Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 101: 1845–1850

    Article  CAS  PubMed  Google Scholar 

  84. Furlan M, Robles R, Solenthaler M, Lammle B (1998) Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 91: 2839–2846

    CAS  PubMed  Google Scholar 

  85. Rieger M, Mannucci PM, Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M et al (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood May 17 [Epub ahead of print]

    Google Scholar 

  86. Tsai HM, Lian ECY (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339: 1585–1594

    Article  CAS  PubMed  Google Scholar 

  87. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, Mc Gee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413: 488–494

    Article  CAS  PubMed  Google Scholar 

  88. Licht C, Stapenhorst L, Simon T, Budde U, Schneppenheim R, Hoppe B (2004) Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolyticuremic syndrome (TTP/HUS). Kidney Int 66: 955–958

    Article  CAS  PubMed  Google Scholar 

  89. Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G (2005) Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement J Am Soc Nephrol 16: 1177–1183

    CAS  PubMed  Google Scholar 

  90. Schärer K (2002) Membranoproliferative Glomerulonephritis. In: K Schärer, O Mehls (eds): Pädiatrische Nephrologie. Springer-Verlag, Berlin, 230–232

    Google Scholar 

  91. Levy Y, George J, Yona E, Shoenfeld Y (1998) Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunol Res 18: 55–60

    CAS  PubMed  Google Scholar 

  92. Schwertz R, de Jong R, Gretz N, Kirschfink M, Anders D, Schärer K and Arbeitsgemeinschaft Pädiatrische Nephrologie (1996) Outcome of idiopathic membranoproliferative glomerulonephritis in children. Acta Paediatr 85: 308–312

    CAS  PubMed  Google Scholar 

  93. Fijen CA, Kuijper EJ, Te Bulte M, van de Heuvel MM, Holdrinet AC, Sim RB, Daha MR, Dankert J (1996) Heterozygous and homozygous factor H deficiency states in a Dutch family. Clin Exp Immunol 105: 511–516

    Article  CAS  PubMed  Google Scholar 

  94. Levy M, Halbwachs-Mecarelli L, Gubler MC, Kohout G, Bensenouci A, Niaudet P, Hauptmann G, Lesavre P (1986) H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 30: 949–956

    CAS  PubMed  Google Scholar 

  95. Vogt BA, Wyatt RJ, Burke BA, Simonton SC, Kashtan CE (1995) Inherited factor H deficiency and collagen type III glomerulopathy. Pediatr Nephrol 9: 11–15

    Article  CAS  PubMed  Google Scholar 

  96. Meri S, Koistinen V, Miettinen A, Tornroth T, Seppala IJ (1992) Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 175: 939–950

    Article  CAS  PubMed  Google Scholar 

  97. West CD (1994) Nephritic factors predispose to chronic glomerulonephritis. Am J Kidney Dis 24: 956–963

    CAS  PubMed  Google Scholar 

  98. West CD, McAdams AJ (1999) The alternative pathway C3 convertase and glomerular deposits. Pediatr Nephrol 13: 448–453

    Article  CAS  PubMed  Google Scholar 

  99. Marder HK, Coleman TH, Forristal J, Beischel L, West CD (1983) An inherited defect in the C3 convertase, C3b,Bb, associated with glomerulonephritis. Kidney Int 23: 749–758

    CAS  PubMed  Google Scholar 

  100. Hogasen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M (1995) Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 95: 1054–1061

    CAS  PubMed  Google Scholar 

  101. Jansen JH, Hogasen K, Grondahl AM (1995) Porcine membranoproliferative glomerulonephritis type II: an autosomal recessive deficiency of factor H. Veterinary Record 137: 240–244

    CAS  PubMed  Google Scholar 

  102. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M (2002) Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 31: 424–428

    CAS  PubMed  Google Scholar 

  103. Hegasy GA, Manuelian T, Hogasen K, Jansen JH, Zipfel PF (2002) The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II. Am J Pathol 161: 2027–2034

    CAS  PubMed  Google Scholar 

  104. Schwertz R, Rother U, Anders D, Gretz N, Schärer K, Kirschfink M (2001) Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a longterm follow-up. Pediatr Allergy Immunol 12: 166–172

    Article  CAS  PubMed  Google Scholar 

  105. Spitzer RE, Stitzel AE, Tsokos GC (1990) Human antiidiotypic antibody responses to autoantibody against alternative pathway C3 convertase. Clin Immunol Immunopathol 57: 19–32

    CAS  PubMed  Google Scholar 

  106. Remuzzi G, Ruggenenti P, Codazzi D, Noris M, Caprioli J, Locatelli G, Gridelli B (2002) Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 359: 1671–1672

    Article  PubMed  Google Scholar 

  107. Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P, Bucchioni S, Sonzogni A, Bonanomi E, Sonzogni V et al (2005) Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor H gene mutation. Am J Transplant 5: 1146–1150

    Article  PubMed  Google Scholar 

  108. Nathanson S, Frémeaux-Bacchi V, Deschênes G (2001) Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. Pediatr Nephrol 16: 554–556

    CAS  PubMed  Google Scholar 

  109. Özcakar ZB, Yalcinkaya F, Derelli E, Acar B, Yüksel S, Tulunay Ö, Ekim M (2004) Favorable outcome of haemolytic uremic syndrome with factor H deficiency. Pediatr Nephrol 19: 815–816

    PubMed  Google Scholar 

  110. Stratton JD, Warwicker P (2002) Successful treatment of factor H-related haemolyticuraemic syndrome. Nephrol Dial Transplant 17: 684–685

    PubMed  Google Scholar 

  111. George JN (2000) How I treat patients with thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Blood 96: 1223–1229

    CAS  PubMed  Google Scholar 

  112. Hayward CP, Sutton DM, Carter WH, Campbell ED, Scott JG, Francombe WH, Shumak KH, Baker MA (1994) Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med 154: 982–987

    Article  CAS  PubMed  Google Scholar 

  113. Jones G, Juszczak M, Kingdon E, Harber M, Sweny P, Burns A (2004) Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 19: 3160–3164

    PubMed  Google Scholar 

  114. Levin A (1999) Management of membranoproliferative glomerulonephritis: evidence-based recommendations. Kidney Int 55: S41–S46

    Article  Google Scholar 

  115. Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, Smyth N, Schulze-Lohoff E, Weber M (2003) Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63: 438–446

    Article  CAS  PubMed  Google Scholar 

  116. Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K, Bloch W, Smyth N, Weber M (2004) Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 19: 1716–1723

    CAS  PubMed  Google Scholar 

  117. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S et al (2005) Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 16: 1392–1403

    Article  PubMed  Google Scholar 

  118. Cunningham PN, Quigg RJ (2005) Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 16: 1214–1222

    Article  CAS  PubMed  Google Scholar 

  119. Alexander J, Pickering MC, Haas M, Osawe I, Quigg RJ (2005) Complement factor H limits immune complex deposition and prevents inflammation and scarring in glomeruli of mice with chronic serum sickness. J Am Soc Nephrol 16: 52–57

    CAS  PubMed  Google Scholar 

  120. Kurtz KA, Schlueter AJ (2002) Management of membranoproliferative glomerulonephritis type II with plasmapheresis. J Clin Apheresis 17: 135–137

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Nephrology, Children’s Hospital of the University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany

    Christoph Licht & Bernd Hoppe

Authors
  1. Christoph Licht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernd Hoppe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knoell Institute, Beutenbergstr. 11a, D-07745, Jena, Germany

    Peter F. Zipfel

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Licht, C., Hoppe, B. (2006). Complement defects in children which result in kidney diseases: diagnosis and therapy. In: Zipfel, P.F. (eds) Complement and Kidney Disease. Progress in Inflammation Research. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7428-4_10

Download citation

Publish with us

Policies and ethics

Search

Navigation